• Khiron's medical cannabis products to be carried at Locatel's large-format pharmacy locations in Colombia
• Locatel is an important pharmacy, healthcare products and medical equipment retailer in Colombia with a database of 2 million patients and customers, and experience managing magistral preparations
• Locatel e-commerce channels enable product deliveries to all markets and territories across Colombia
• Locatel's operations deemed an essential service in Colombia during COVID-19 pandemic, ensuring continued access to filling and delivery of prescriptions

TORONTO, April 22, 2020 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, announces that it has entered into a sales and distribution agreement with Locatel, a pharmacy, healthcare products, and medical equipment retailer with a database of over 2 million patients in Colombia. The agreement immediately brings Khiron's medical cannabis products to Locatel's pharmacies and medical equipment stores in Bogota and Cartagena.

"Khiron is the only company to have all necessary permits and certificates to sell medical cannabis in Colombia, and now the focus is on service and solving patient needs for the last mile," comments Alvaro Torres, Khiron CEO and director. "The Locatel brand is highly respected among Colombians and the company's philosophy aligns with our own. We look forward to partnering with Locatel to improve access to medical cannabis for patients throughout the country."

Effective immediately Khiron's low-THC, CBD-rich magistral preparations will be available through Locatel stores across Colombia's largest urban centres, including in Bogota, with a population of 10 million, and Cartagena, with a population of 1 million.

"This has always been about providing people with medicine they vitally need, and it must be available with home delivery, and for pick up at trusted locations such as Locatel," Torres continued.

"With our large customer network, customer database, and commitment to patient health, working with Khiron is a clear strategic opportunity for both organizations. Like us, Khiron is focused on patient care and we commend them for achieving this milestone to bring medical cannabis to Colombia," comments Eurice Troya, CEO Locatel Colombia.

About Locatel
With an integrated health concept, Locatel offers products, services, events and educational programs that help customers maintain or recover their quality of life. The company operates health markets in Colombia, Venezuela and the US, and prides itself on exemplary customer service and resources delivering better patient care. Please visit: https://www.locatelcolombia.com/ 

About Khiron Life Sciences Corp.
Khiron Life Sciences Corp. is the dominant integrated medical cannabis company in Latin America. Khiron has core operations in Latin America, along with activity in North America and Europe, and is licensed in Colombia for the cultivation, production, domestic distribution, and international export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis. The Company delivers best in class regulatory compliance, has the first approved line of CBD cosmetic products on shelf in Colombia, and is fully authorized to manufacture high- and low-THC medical cannabis, and to fill prescriptions for low-THC medical cannabis in the country.

With a focused regional strategy and patient oriented approach, the Company combines global scientific expertise, agricultural advantages, branded product market entrance experience and education to drive prescription and brand loyalty to address priority medical conditions such as chronic pain, epilepsy, depression and anxiety in the Latin American market of over 620 million people. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced executive team, and a knowledgeable Board of Directors that includes former President of Mexico, Vicente Fox. 

Visit Khiron online at investors.khiron.ca and on Instagram @khironlife

Cautionary Notes

Forward-Looking Statements

This press release may contain certain "forward-looking information" and "forward-looking statements" within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron's control, including the risk factors discussed in Khiron's Annual Information Form which is available on Khiron's SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and are made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

United States Disclaimer

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons (as such term is defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

View original content to download multimedia:http://www.prnewswire.com/news-releases/khiron-signs-medical-cannabis-distribution-deal-in-colombia-with-locatel-301044918.html

SOURCE Khiron Life Sciences Corp.